Brought to you by 
Sangart's Series G round brings in $50mm
04 May 2011
Executive Summary
Sangart Inc. (developing therapies that enhance oxygen delivery to deprived tissues) raised $50mm through its Series G round. Three existing investors, including leader Leucadia National Corp., received equity and warrants, and could commit to another $2.55mm in funding according to a Form D filed by the company. Sangart will use the proceeds to continue work on its two lead candidates--MP4OX for severe traumatic hemorrhage and MP4CO for sickle cell disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com